COMPANY PROFILE // THE 014 REPORT
Prothena Corp. Public Ltd Co
PRTA (Nasdaq) · Formerly: Prothena Corp plc; Neotope Corp Ltd
Assembled from 2 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 26 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
PROTHENA CORP PUBLIC LTD CO is an SEC-registered operating company in pharmaceutical preparations, incorporated in Israel, based in Dublin 2, Israel; listed as PRTA (Nasdaq).[source] It reported revenue of $9.7 million for the fiscal year ended 2025-12-31.[source] It has filed 79 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-19.[source] Its largest institutional holders on 13F filings are FMR LLC, Rubric Capital Management LP, BlackRock, Inc. (as of 2026-06-30).[source] Every list and source checked for this page came back clear (26 of 26), dated in the checks panel.[source]
- red0
- amber0
- info0
- FMR LLC$70.5M
- Rubric Capital Management LP$49.0M
- BlackRock, Inc.$47.7M
- STATE STREET CORP$23.4M
- VANGUARD PORTFOLIO MANAGEMENT LLC$16.2M
- D. E. Shaw & Co., Inc.$15.8M
- ADAR1 Capital Management, LLC$15.2M
- TWO SIGMA INVESTMENTS, LP$12.4M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Kinney Gene G. · President and CEO (Director,Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Malecek Michael J · Chief Legal Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Nguyen Tran · Chief Strategy Officer and CFO (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Smith Brandon S. · Chief Operating Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Swanson Chad J. · Chief Development Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Walker Karin L · Chief Accounting Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- Zago Wagner M. · Chief Scientific Officer (Officer) · latest Form 4 2026-03-05 · filing · LinkedIn search
- COLLIER RICHARD T · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Cobb Paula K · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Cooke Shane · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Dunn William H. Jr. · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
- Ekman Lars · Director · latest Form 4 2025-05-16 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001559053 | source |
| EIN | 00-0000000 | source |
| Business address (SEC) | 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2, L2, D02 VK60 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-16 · in 115 days · Next 10-K due (period ended 2026-12-31; Accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 170 days · Next 10-Q due (period ended 2027-03-31; Accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Alkermes plc. · Cooke Shane
- Aktis Oncology, Inc. · Kim Helen Susan
- Ultragenyx Pharmaceutical Inc. · WELCH DANIEL G
- Structure Therapeutics Inc. · WELCH DANIEL G
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-29 filing 8-K items 1.02,9.01 · SEC EDGAR
- 2026-10-02 officer change 8-K items 5.02 · SEC EDGAR
- 2026-08-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-29 filing 144 · SEC EDGAR
- 2026-07-29 filing 144 · SEC EDGAR
- 2026-06-09 filing 144 · SEC EDGAR
- 2026-05-15 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-27 filing ARS · SEC EDGAR
- 2026-03-27 filing DEFA14A · SEC EDGAR
- 2026-03-27 filing Proxy statement · SEC EDGAR
- 2026-03-02 filing EFFECT · SEC EDGAR
- 2026-02-27 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-02-27 filing POS AM · SEC EDGAR
- 2026-02-27 filing Annual report (10-K) · SEC EDGAR
- 2026-02-27 filing POSASR · SEC EDGAR
- 2026-02-19 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-12-12 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2025-11-19 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2025-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-11-06 filing DEFA14A · SEC EDGAR
- 2025-11-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-10-07 filing DEFA14A · SEC EDGAR
- 2025-10-07 filing Proxy statement · SEC EDGAR
- 2025-09-25 filing PRE 14A · SEC EDGAR
- 2025-08-27 filing 8-K items 8.01,9.01 · SEC EDGAR
132 earlier entries
- 2025-08-08 filing S-8
- 2025-08-06 filing 8-K items 8.01,9.01
- 2025-08-04 filing Quarterly report (10-Q)
- 2025-08-04 filing 8-K items 2.02,9.01
- 2025-07-30 officer change 8-K items 5.02,9.01
- 2025-07-30 insider First Form 3/4/5 on record for Kinney Gene G. (President and CEO)
- 2025-07-30 insider First Form 3/4/5 on record for Malecek Michael J (Chief Legal Officer)
- 2025-07-30 insider First Form 3/4/5 on record for Nguyen Tran (Chief Strategy Officer and CFO)
- 2025-07-30 insider First Form 3/4/5 on record for Smith Brandon S. (Chief Operating Officer)
- 2025-07-30 insider First Form 3/4/5 on record for Swanson Chad J. (Chief Development Officer)
- 2025-07-30 insider First Form 3/4/5 on record for Walker Karin L (Chief Accounting Officer)
- 2025-07-30 insider First Form 3/4/5 on record for Zago Wagner M. (Chief Scientific Officer)
- 2025-06-18 officer change 8-K items 2.05,5.02
- 2025-06-16 filing 8-K items 8.01,9.01
- 2025-05-29 filing SCHEDULE 13D/A
- 2025-05-23 filing 8-K items 8.01,9.01
- 2025-05-16 officer change 8-K items 5.02,5.07,9.01
- 2025-05-16 insider First Form 3/4/5 on record for COLLIER RICHARD T (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Cobb Paula K (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Cooke Shane (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Dunn William H. Jr. (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Ekman Lars (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Kim Helen Susan (Director)
- 2025-05-16 insider First Form 3/4/5 on record for Selkoe Dennis J. (Director)
- 2025-05-16 insider First Form 3/4/5 on record for WELCH DANIEL G (Director)
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-05-06 filing SCHEDULE 13D/A
- 2025-03-28 filing ARS
- 2025-03-28 filing DEFA14A
- 2025-03-28 filing Proxy statement
- 2025-02-27 filing Annual report (10-K)
- 2025-02-20 filing 8-K items 2.02,9.01
- 2025-01-03 filing SCHEDULE 13D/A
- 2024-12-30 officer change 8-K items 5.02
- 2024-11-12 filing 8-K items 2.02,9.01
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-09-27 officer change 8-K items 5.02,7.01,9.01
- 2024-08-08 filing S-8
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-05-28 filing 8-K items 1.01,8.01
- 2024-05-17 officer change 8-K items 5.02,5.07,9.01
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-08 filing 8-K items 2.02,9.01
- 2024-03-29 filing ARS
- 2024-03-29 filing DEFA14A
- 2024-03-29 filing Proxy statement
- 2024-02-22 filing S-3ASR
- 2024-02-22 filing Annual report (10-K)
- 2024-02-21 officer change 8-K items 5.02
- 2024-02-15 filing 8-K items 2.02,9.01
- 2024-01-24 filing 144
- 2024-01-08 filing 8-K items 2.02,8.01,9.01
- 2023-12-20 filing 144
- 2023-11-30 filing 144
- 2023-11-02 filing Quarterly report (10-Q)
- 2023-11-02 filing 8-K items 2.02,9.01
- 2023-10-25 filing 144
- 2023-10-11 filing 144
- 2023-10-04 filing 144
- 2023-09-27 filing 144
- 2023-09-25 filing 144
- 2023-09-19 filing 144
- 2023-09-13 filing 144
- 2023-09-13 filing 144
- 2023-09-06 filing 144
- 2023-08-30 filing 144
- 2023-08-23 filing UPLOAD
- 2023-08-18 filing 144
- 2023-08-16 filing 144
- 2023-08-16 filing 144
- 2023-08-04 filing CORRESP
- 2023-08-03 filing S-8
- 2023-08-03 filing Quarterly report (10-Q)
- 2023-08-03 filing 8-K items 2.02,9.01
- 2023-08-02 filing 144
- 2023-08-02 filing 144
- 2023-07-26 filing 144
- 2023-07-25 filing UPLOAD
- 2023-07-19 filing 144
- 2023-07-12 filing 144
- 2023-07-12 filing 144
- 2023-07-10 filing 8-K items 1.01
- 2023-07-05 filing 144
- 2023-07-05 filing 144
- 2023-07-03 filing 144
- 2023-06-28 filing 144
- 2023-06-20 filing 144
- 2023-06-16 filing 144
- 2023-06-14 filing 144
- 2023-06-14 filing 144
- 2023-06-14 filing 144
- 2023-06-07 filing 144
- 2023-06-07 filing 144
- 2023-05-31 filing 144
- 2023-05-19 officer change 8-K items 5.02,5.07,9.01
- 2023-05-19 filing 144
- 2023-05-17 filing 144
- 2023-05-17 filing 144
- 2023-05-16 officer change 8-K items 5.02
- 2023-05-04 filing Quarterly report (10-Q)
- 2023-05-04 filing 8-K items 2.02,9.01
- 2023-05-03 filing 144
- 2023-04-28 officer change 8-K items 5.02
- 2023-04-26 filing 144
- 2023-04-19 filing 144
- 2023-03-31 filing ARS
- 2023-03-31 filing DEFA14A
- 2023-03-31 filing Proxy statement
- 2023-03-10 filing 8-K items 7.01
- 2023-02-28 filing Annual report (10-K)
- 2023-02-23 filing 8-K items 2.02,9.01
- 2022-12-16 filing 8-K items 8.01,9.01
- 2022-12-16 filing 424B5
- 2022-12-13 filing 424B5
- 2022-11-21 filing 8-K items 8.01,9.01
- 2022-11-03 filing Quarterly report (10-Q)
- 2022-11-03 filing 8-K items 2.02,9.01
- 2022-10-31 filing 8-K items 1.01,9.01
- 2022-09-01 officer change 8-K items 5.02
- 2022-08-10 filing S-8
- 2022-08-08 filing Quarterly report (10-Q)
- 2022-08-08 filing 8-K items 2.02,9.01
- 2022-05-20 officer change 8-K items 5.02,5.07,9.01
- 2022-05-05 filing Quarterly report (10-Q)
- 2022-05-05 filing 8-K items 2.02,9.01
- 2022-05-05 filing DEFA14A
- 2022-04-26 filing 8-K items 8.01,9.01
- 2022-04-25 filing DEFA14A
- 2020-05-22 name change Name changed from Prothena Corp plc
- 2012-10-01 name change Name changed from Neotope Corp Ltd
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-05 (within 30 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-29 (within 30 days) 8-K filed: Item 1.02 agreement terminated; Item 9.01 exhibits
- 2026-10-02 (older) 8-K filed: Item 5.02 officer or director change
- 2026-08-06 (older) 10-Q filed
- 2026-08-06 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-15 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-05-07 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:PRTA The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1559053 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | PRTA / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| CUSIP | G72800108 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001559053 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $9,684,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 11:39 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$244,092,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 11:39 UTC | Report an error |
| Total assets (at 2025-12-31) | $326,804,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 11:39 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $280,474,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 11:39 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $307,531,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 11:39 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| State of incorporation | L2 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| Business address | 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, GRAND CANAL DOCKLANDS, DUBLIN 2, L2, D02 VK60 | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-19 | SEC EDGAR company profile | as filed | 2026-11-21 11:39 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$163,580,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 11:39 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $8,373,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D total offering amount (D filed 2018-03-29) | $49,999,997 | 2018-03-29 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D total amount sold (D filed 2018-03-29) | $49,999,997 | 2018-03-29 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D industry group | Biotechnology | 2018-03-29 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2018-03-29 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
| Form D date of first sale | 2018-03-21 | 2018-03-29 | D | as filed | 2026-11-21 11:39 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-05 · accession 0001559053-26-000031
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $620,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001559053-26-000031 | 2026-11-21 11:39 UTC | Report an error |
| Net income (loss) | -$16,509,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-05 | 0001559053-26-000031 | 2026-11-21 11:39 UTC | Report an error |
| Cash and cash equivalents | $271,368,000 | at 2026-09-30 | 10-Q | 2026-11-05 | 0001559053-26-000031 | 2026-11-21 11:39 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-05 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-29 Filing 8-K filed: Item 1.02 agreement terminated; Item 9.01 exhibits
- 2026-10-02 Filing 8-K filed: Item 5.02 officer or director change
- 2026-08-06 Filing 10-Q filed
- 2026-08-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-15 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-03-27 Filing ARS filed
- 2026-03-27 Filing DEFA14A filed
- 2026-03-27 Filing DEF 14A filed
- 2026-03-02 Filing EFFECT filed
- 2026-02-27 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-02-27 Filing POS AM filed
- 2026-02-27 Filing 10-K filed
- 2026-02-27 Filing POSASR filed
- 2026-02-19 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-12-12 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2025-11-19 Filing 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2025-11-06 Filing 10-Q filed
- 2025-11-06 Filing DEFA14A filed
- 2025-11-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-10-07 Filing DEFA14A filed
- 2025-10-07 Filing DEF 14A filed
8-K item text, as filed (excerpts)
- 2026-11-05 8-K Item 2.02, Results of Operations and Financial Condition
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically incorporate by reference the information furnished pursuant to Item 2.02 (including Exhibit 99.1) of this Current Report. On November 5, 2026, Prothena Corporation plc issued a press release announcing its financial results for the third quarter ended… the 8-K · retrieved 2026-11-21 11:39 UTC - 2026-10-29 8-K Item 1.02, Termination of a Material Definitive Agreement
Following an internal strategic review, Bristol Myers Squibb informed Prothena Corporation plc (the “Company”) on October 28, 2026 that it has decided not to advance PRX019 further in the clinic. In May 2024, a subsidiary of the Company entered into an exclusive global license agreement for PRX019 with Bristol Myers Squibb (the “PRX019 Global License Agreement”) to develop, manufacture and commercialize antibody products globally targeting a specified target (including PRX019, and collectively, “Licensed Products”) for any and all uses or purposes with respect to any human or animal disease, disorder or condition, and received an upfront payment of $80 million. The PRX019 License Agreement… the 8-K · retrieved 2026-11-21 11:39 UTC - 2026-08-06 8-K Item 2.02, Results of Operations and Financial Condition
The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically incorporate by reference the information furnished pursuant to Item 2.02 (including Exhibit 99.1) of this Current Report. On August 6, 2026, Prothena Corporation plc issued a press release announcing its financial results for the second quarter ended… the 8-K · retrieved 2026-11-21 11:39 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $70,480,344 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 2 | Rubric Capital Management LP | $48,950,000 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 3 | BlackRock, Inc. | $47,657,280 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 4 | STATE STREET CORP | $23,431,621 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | $16,166,158 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 6 | D. E. Shaw & Co., Inc. | $15,776,164 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 7 | ADAR1 Capital Management, LLC | $15,218,898 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 8 | TWO SIGMA INVESTMENTS, LP | $12,384,223 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 9 | Palo Alto Investors LP | $11,191,487 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $11,024,980 | 2026-06-30 | SEC 13F filing | 2026-11-21 11:39 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1559053.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001559053. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.